Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HHS opposes pediatric legislation

This article was originally published in The Gray Sheet

Executive Summary

HHS Secretary Michael Leavitt is expressing "major concerns" about pediatric device language in the FDA Revitalization Act (S 1082), which cleared the Senate Health, Education, Labor and Pensions Committee April 18. In an April 17 letter to HELP Chairman Sen. Edward Kennedy, D-Mass., Leavitt writes that HHS opposes provisions that sanction government funding of research run by private consortia and allow firms to profit from devices approved under a humanitarian device exemption. The pediatric device section of the bill is intended to offer incentives to manufacturers to develop devices for children and adolescents (1"The Gray Sheet" April 2, 2007, p. 25). Amendments could be added to the legislation, which also includes provisions reauthorizing medical device and pharmaceutical user fee programs, before the full Senate votes on the measure...

You may also be interested in...



Dodd Aims For Quick Passage Of Pediatric Device Legislation

Sen. Christopher Dodd, D-Conn., is pushing for quick action on legislation to provide incentives for the development of pediatric medical devices

US FDA Pharmaceutical Quality Office Lauds Continuous Manufacturing Approvals

The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.

Warning Letter Roundup & Recap – 19 February 2020

No device-related warning letters were released by the US FDA the week of 19 February.

UsernamePublicRestriction

Register

MT024712

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel